Influences of the genotypes of HBV and HBeAg regarding their response to PEG-IFN in chronic hepatitis B patients.
- Author:
He-bin FAN
1
;
Ya-bing GUO
;
Kang-xian LUO
;
Jin-lin HOU
;
Zhan-hui WANG
;
Ming-xia ZHANG
Author Information
- Publication Type:Journal Article
- MeSH: Adult; Antiviral Agents; therapeutic use; Female; Genotype; Hepatitis B e Antigens; blood; Hepatitis B virus; genetics; immunology; Hepatitis B, Chronic; drug therapy; virology; Humans; Interferon-alpha; therapeutic use; Male; Polyethylene Glycols; therapeutic use; Recombinant Proteins; Treatment Outcome
- From: Chinese Journal of Hepatology 2005;13(7):488-490
- CountryChina
- Language:Chinese
-
Abstract:
OBJECTIVETo study the effects of genotypes of HBV and HBeAg on the response to PEG-interferon alpha (PEG-IFN) in chronic hepatitis B (CHB) patients.
METHODSPCR-RFLP and S gene sequencing were conducted in 42 CHB patients.
RESULTSThe sustained response (SR) rates were 66.7% in genotype B and 27.3% in genotype C group. The P value was 0.039 by the Pearson Chi-square test, while it was 0.06 by the Fisher's exact test. The results suggested a trend that patients with genotype B HBV compared to genotype C had better SR to PEG-IFN therapy, although the difference was not significant. Results also showed that SR rate in patients with HBeAg-negative CHB (7/8 87.5%) was significantly higher than that in HBe+ CHB patients (8/21 38.1%, P < 0.05).
CONCLUSIONOur results indicate that HBV genotype and HBeAg, especially the later, are main factors for predicting PEG-IFN therapy response in CHB patients.
